Important Notice – Fraudulent Emails
0
Patrys Ltd has been informed that fraudulent emails purporting to be sent from our Company are in circulation. The fraudulent…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30…
AusBiotech Conference | Australia Biotech Invest & Partnering Conference
Patrys CEO, Dr James Campbell, has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech…
Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model
Patrys today released the latest data from its completed proof-of-concept study demonstrating the potential of its full-sized deoxymab antibody, PAT-DX3,…
Patrys AGM – 5th Nov 2021
The Patrys Ltd team is pleased to invite you to a virtual webinar for our Annual General Meeting (AGM): WHEN:…
Video Presentation | Proactive Lifesciences Webinar
Patrys CEO and MD, Dr James Campbell, recently participated in a webinar hosted by Proactive to summarise Patrys’ key value…
Proactive Lifesciences Webinar, 28 September 2021
Join Patrys’ CEO and Managing Director Dr James Campbell at 12pm AEST on Tuesday 28 September 2021 for the Proactive…
Bioshares | September 2021
An update on Patrys has been published in the latest issue of investor newsletter Bioshares this week. Titled ‘Patrys Demonstrates…
AusBiz | Dr James Campbell
It was encouraging to see the market respond positively to Patrys’ (ASX:PAB) announcement of its preclinical study highlighting the potential…
Patrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)
Today Patrys announced new data from a successful preclinical study highlighting the potential for using our deoxymab antibodies as targeting…